Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 15Phase 1/2 14Phase EARLY_PHASE1 6Phase 3 6Phase NA 2Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 118Urinary Bladder Neoplasms 27Carcinoma, Renal Cell 25Kidney Neoplasms 19Neoplasms 14Neoplasm Metastasis 9Breast Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Prostatic Hyperplasia 5Pain 5Lung Neoplasms 5Liver Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Multiple Myeloma 3Kidney Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Tobacco Use Disorder 2Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Cancer Metastatic 2Pancreatic Neoplasms 2

Interventions

olaparib 1enzalutamide 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Metastatic Castration-resistant Prostate Cancer × Genitourinary × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡